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Abstract While treatment options are available, excessive
daytime sleepiness (EDS) remains a significant unmet medical
need for many patients. Relatively little rodent behavioural
pharmacology has been conducted in this context to assess
potential pro-vigilant compounds for their ability to restore
functional capacity following experimentally induced sleep
loss. Male Wistar rats were prepared for electroencephalo-
graphic (EEG) recording and subject to 11 h of sleep restric-
tion using a biofeedback-induced cage rotation protocol. A
simple response latency task (SRLT) was used to
behaviourally index sleep restriction and the effects of pro-
vigilant compounds: modafinil, D-amphetamine, caffeine,
and the mGlu5-positive allosteric modulator LSN2814617.
Sleep restriction resulted in a consistent, quantified loss of
non-rapid eye movement (NREM) and REM sleep that im-
paired SRLT performance in a manner suggestive of progres-
sive task disengagement. In terms of EEG parameters, all
compounds induced wakefulness. Amphetamine treatment
further decreased SRLT performance capacity, whereas the
other three compounds decreased omissions and allowed an-
imals to re-engage in the task. Caffeine and modafinil also
significantly increased premature responses during this peri-
od, an effect not observed for LSN2814617. While all com-
pounds caused compensatory sleep responses, the magnitude
of compensation observed for LSN2814617 was much small-
er than would be predicted to result from the prolongation of
wakefulness exhibited. Using simple response latencies to in-
dex performance, an mGlu5 PAM dramatically increased
wakefulness and improved functional capacity of sleep-
restricted animals, without eliciting a proportionate compen-
satory sleep response. This effect was qualitatively distinct
from that of amphetamine, caffeine and modafinil.
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Introduction
Sleep deprivation and the cognitive sequelae of excessive day-
time sleepiness (EDS) are prevalent in modern society. EDS
presents in insomnia, sleep apnea and narcolepsy (Roth and
Roehrs 1996) and often also as a complication of other neu-
ropsychiatric disorders, such as Parkinson’s disease, multiple
sclerosis, chronic pain and depression (e.g. see reviews by
Boulos and Murray 2010; Chellappa et al. 2009; Knie et al.
2011). Whilst recovery sleep is the best known remedy for
EDS, this is often unattainable, especially for patients
exhibiting comorbidity. Unmet clinical need remains for phar-
macotherapies that can restore cognitive deficits during EDS,
ideally lacking potential for causing debilitating rebound
hypersomnolence.
Beyond the well-established effects of caffeine, amphet-
amine andmodafinil, several studies have already investigated
novel pharmacological countermeasures for cognitive impair-
ment caused by extendedwakefulness in animals, for example
AMPAkines (Porrino et al. 2005), histamine H3 receptor an-
tagonists (Stocking and Letavic 2008), serotonin 5HT6
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receptor agonists (Ly et al. 2013) and orexin receptor agonists
(Deadwyler et al. 2007). However, little preclinical behaviour-
al work so far has focused on sleep-restricted rodents or ex-
plored the utility of simple response latency testing in the rat
as a translational homologue of the human psychomotor vig-
ilance task (PVT) for detection of pro-vigilant pharmacologi-
cal effects. Aspects of attentional performance are typically
the first and most sensitive processes to be negatively affected
by sleep loss/EDS (Balkin et al. 2004). This is of significant
functional consequence as deficits in sustained or vigilant at-
tention are likely to be the root cause of sleep loss-related
accidents (Akerstedt et al. 2011), and it is easy to hypothesize
how attentional deficits could underlie or catalyze other types
of cognitive deficit in this context. The PVTwas developed to
measure exactly this type of vigilant or sustained attention in
human studies of sleep loss and performance capacity (Balkin
et al. 2004; Dinges and Powell 1985). It tests simple reaction
times (RTs) to a visual cue occurring at variable inter-stimulus
intervals over a short period. The PVT is known to be sensitive
to both circadian and homeostatic sleep drives (Van Dongen
and Dinges 2000). Sleep deprivation causes a general slowing
of RTs in PVT, where an especially sensitive measure in
humans is the worsening of slower RTs: >500 ms latencies
known as performance Blapses^ (Anderson et al. 2010; Basner
and Dinges 2011). However, as well as performance lapses,
increased errors of omission and commission, and an enhance-
ment of time-on-task detriments are all evident deprivation-
related deficits (Lim and Dinges 2008).
Previous reports have highlighted the potential of metabo-
tropic glutamate receptor 5 (mGlu5) positive allosteric modu-
lators (PAMs) to mediate wake-promoting effects of apparent-
ly large magnitude in rats (Gilmour et al. 2013; Gregory et al.
2013). However, it is not clear from the previous work, which
focused assessment only on EEG-sleep/wake state parameters
in rested animals, whether mGlu5 PAM-induced wakefulness
extends to states of sleep restriction, and further whether it is
functionally beneficial. The aim of this paper therefore was to
directly compare an mGlu5 PAM, namely LSN2814617, to
the known wake-promoting agents modafinil, caffeine and
amphetamine on the performance of a simple response latency
task (SRLT) in the rat following biofeedback-induced sleep
restriction.
Methods
Biofeedback-induced sleep restriction All experimental
protocols were approved by the local ethics committee and
carried out in accordance with the UK Animals (Scientific
Procedures) Act 1986. Adult, maleWistar rats (approximately
270–300 g at time of surgery, Charles River Laboratories,
Margate, UK) were prepared with cranial implants for chronic
electroencephalogram (EEG) and electromyogram (EMG)
recording (Supplement S1). Following SRLT training as de-
scribed below, animals were housed individually in custom-
designed, sleep deprivation chambers for the duration of the
experiment. Each chamber consisted of a cylinder (39.7 cm
diameter by 32.1 cm length) constructed of plexiglass rods,
positioned horizontally inside a Plexiglas frame (637.2 cm2
floor space). The study was conducted in a sound-attenuated,
light and temperature-controlled recording room, to control
for sensory modalities known to affect sleep. The cranial im-
plants were connected to ultra-low-torque slip-ring commuta-
tors (Hypnion, Inc., Lexington, MA, USA) by metal coil re-
inforced flexible cables, allowing for free, unrestrained move-
ment throughout the cage. When an epoch of NREM or REM
sleep was detected, the program (SCORE-2004™; see Sup-
plement S1) activated a motor to rotate the cylindrical cham-
ber around its axis for 10 s at a rate of 18.3 cm/s. This gives a
mild vestibular stimulus sufficient to cause immediate awak-
ening and a small amount of locomotion during the short
period of rotation. The direction in which the chamber rotated
was pseudorandomly determined each time. Each 10 s epoch
in which a rotation occurred reflected an attempt to enter
NREM or REM sleep.
Simple response latency task SRLT testing was conducted
in standard operant boxes housed in sound and light attenua-
tion chambers (Med Associates, US). Food pellets (Noyes,
45 mg, Formula P) were delivered from an automatic pellet
dispenser. The houselight and magazine light provided prepa-
ratory and imperative cues, respectively. Experimental ses-
sions were controlled and data recorded by programs written
in-house using MedPC IV software (Med Associates, UK).
Operant boxes were equipped with dummy commutators so
that EEG implant tethers could be connected to prevent them
from disturbing the implanted animals during testing.
Training Following recovery from surgery rats were main-
tained on food restriction until they reached the final training
programme and then returned to ad libitum food. Animals
were trained on the task in a series of successive approxima-
tions during daily 30 min sessions. In the first stage, the mag-
azine light/imperative cue was illuminated for 10 s (with a 30 s
inter-trial interval) during which a nosepoke would earn a
food pellet reward. Food reward would be delivered at the
end of this cue even if no nosepoke was made. The
houselight/preparatory cue remained illuminated throughout
the session except for 5-s timeout periods that occurred while
the animal collected food rewards. Animals were required to
make at least ten nosepokes to advance to the second stage,
where all rewards had to be obtained by nosepoke. If the
animal did not make a nosepoke during the presentation of
the imperative cue, an omission was recorded that resulted in a
5-s timeout period with no light stimulus. After completing
>75% of trials available over two consecutive sessions,
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animals could progress to the third stage where they had to
learn to inhibit premature responding during the preparatory
cue. Thus, a trial would be initiated by illumination of the
houselight and responding had to be inhibited until illumina-
tion of the magazine light. During this stage, the interval be-
tween preparatory and imperative cue was fixed at 5 s. Pre-
mature responses during the preparatory cue resulted in a
timeout period. Again, the criterion for progression to the next
stage of training was completion of >75% of trials available
over two consecutive sessions. Where necessary, animals
finding it difficult to meet this criterion would be subjected
to remedial training using shorter fixed intervals between
cues. In the final stage of training, a variable interval (range
4–6 s) was introduced between preparatory and imperative
cues to prevent animals from timing responses precisely. From
the SRLT, the number of trials completed, head entries made
and response errors (premature responses and omissions) were
counted, RTs, premature response latencies and the times at
which both occurred during the session were also collected.
SRLT testing protocol is illustrated in Fig. 1.
Drugs D-amphetamine sulfate (Sigma Aldrich, UK) was dis-
solved in 5 % (w/v) glucose solution and administered subcu-
taneously at a volume of 1 ml/kg, in doses of 0.5, 1 and
2 mg/kg. Modafinil (Apin Chemicals UK) was dissolved in
0.25 % methylcellulose (15 cP) and administered intraperito-
neally at a volume of 2 ml/kg, in doses of 30, 100 and
300 mg/kg. LSN2814617 [(7S)-3-tert-butyl-7-[3-(4-
fluorophenyl)-1,2,4-oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,
4]triazolo[4,3-A]pyridine (Lilly Research Labs)] was
suspended in 1 % (w/v) carboxymethyl cellulose,
complemented with addition of 0.25 % Tween 80 and
0.05 % antifoam. It was administered orally at a volume of
1 ml/kg, in doses of 1, 3 and 10 mg/kg. Caffeine (Lilly Re-
search Labs) was dissolved in 0.25 % methylcellulose (15 cP)
and administered intraperitoneally at a volume of 2 ml/kg, in
doses of 4, 8 and 12 mg/kg. All doses refer to free base or acid
weights of compounds.
Study design Sleep restriction protocols were run in a within-
subjects crossover study design, where rats were pseudo-
randomly assigned using a Latin square to one drug treatment
condition per week. Each compound was tested in a separate
experiment, and between experiments new animals were used
(n=95). Both a 300 mg/kg treatment of modafinil and a
3 mg/kg treatment of LSN 2814617 acted as positive controls
to enable bridging between experiments. For the final analy-
sis, modafinil and LSN 2814617 treatment groups were com-
bined across studies resulting in larger sample sizes for these
drugs.
To administer a drug treatment, rats were removed from
their cage for about 60–90 s to be dosed. At least 7 days
Bwashout^ was allowed preceding and following treatments
with no duplication of treatment within an animal. Prior to
each study, all subjects underwent a 5-h sleep restriction pro-
cess to habituate animals to the procedure. All drugs were
dosed at circadian time 10.5 (CT-10.5; 10.5 h after lights on,
LD 12:12). For 3 consecutive days (BPre^, BTest^ and
BPost^), animals were removed from sleep deprivation wheels
and placed immediately into operant boxes for a 40-min SRLT
session. On BTest^ day, SRLT testing occurred immediately
following an 11-h sleep restriction period from CT0 to CT11.
On BPre^ and BPost^ days, rats underwent SRLT testing be-
tween CT3 and CT5. Study design is depicted in Fig. 2. For
REM andNREM sleep parameters, differential measures were
calculated between baseline BPre^ day phase data and four
other sections of BTest^ and BPost^ day phase data: BSleep
Deprivation^=Test Day Light Phase–Pre Day Light Phase,
indexing the direct effect of the sleep restriction process rela-
tive to a normal resting phase; BDrug Treatment^=Test Day
Fig. 1 Task overview. Following an inter-trial interval (20 s), the
houselight is illuminated to serve as a preparatory cue. After a 5-s
variable interval (range 4–6 s), the magazine light is illuminated to
serve as an imperative cue. A head entry made during the 10 s period
when the maglight is on will result in the delivery of a food pellet. Head
entries made before magazine light onset are recorded as premature
responses, and a failure to respond to the magazine light is recorded as
an omission. Both premature responses and omissions are Bpunished^
with a 5-s time out period
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Dark Phase–Pre Day Dark Phase, indexing the effect of drug
treatment during the post-sleep restriction waking phase rela-
tive to a normal waking phase; BRecovery – Light^=Post Day
Light Phase–Pre Day Light Phase, indexing the potential for
recovery sleep following sleep restriction and drug treatment
in the subsequent light phase by comparing the BPost^ day
resting phase relative to a normal resting phase; BRecovery –
Dark^=Post Day Dark Phase–Pre Day Dark Phase, indexing
the potential for recovery sleep following sleep restriction and
drug treatment in the subsequent dark phase by comparing the
BPost^ day waking phase relative to a normal waking phase.
Following exclusion of datasets that were subject to technical
error, each drug study comprised of the following sample
sizes: modafinil, n=21; D-amphetamine, n=13; caffeine, n=
11; LSN2814617, n=23. No other exclusion criteria were ap-
plied to datasets.
Statistics All data were analyzed using Statistica v9.0
(Statsoft Ltd, Bedford, UK). For general sleep/wake state pa-
rameter assessments, the first 5 h following drug administra-
tion were analyzed with repeated measures ANOVA, with
BTreatment^ and BTime^ as within-subjects factors. Planned
comparisons of each treatment group compared to the vehicle
group were also conducted at each time point for each drug.
SRLT task parameters were analyzed with repeated measures
ANOVA, with BTreatment^ and BDay^ as within-subjects fac-
tors. Planned comparisons were then conducted, where re-
spective vehicle- and drug-treated groups were compared be-
tween Pre Day–Test Day and Pre Day–Post Day, and also for
each separate day a planned comparison was made between
the vehicle group and the drug-treated group. Drug effects on
REM and NREM sleep differential measures were analysed
using. ANOVAs with BTreatment^ as a within-subject factor.
Results
Full details of results of statistical analyses calculated for all
datasets can be found as Electronic Supplementary Material
(Supplement S2).
General sleep/wake parameters A baseline period of 24 h
was used to evaluate the sleep history of individual animals
prior to treatment. During this time, all rats displayed a circa-
dian rhythm in sleep, activity and body temperature that was
consistent between treatment groups. As depicted in Fig. 3, in
the face of 11 h of sleep restriction, all four compounds
Fig. 2 Study design. Rats were kept on a Light (L) phase–Dark (D)
phase 12:12 cycle (8.00 a.m–8.00 p.m.). For baseline data, rats
underwent simple response latency testing at Circadian Time (CT) 3–5
on BPre^ day. On BTest^ day sleep deprivation commenced at onset of
Light Phase and was continued for 11 h (CT0-CT11). All drugs were
dosed at CT10.5 (10.5 h after lights on). At CT11 animals were
removed from sleep deprivation wheels and placed immediately into
operant boxes for a 40-min SRLT session. Rats were then retested in
the SRLT on BPost^ day between CT 3–5
Fig. 3 The effect of pro-vigilant compounds on wakefulness in rats. The
graphs on the left depict a 72 h plot of wakefulness for modafinil, D-
amphetamine, caffeine and LSN2814617 studies, thereby including
“Pre”, “Test” and “Post” drug administration days. The x-axis depicts
Circadian Time, where the solid bars above the bottom x-axis between
CT12-0 indicate when dark phases occurred. Vertical dotted lines at CT0
and CT11 depict the beginning and end of the sleep restriction period,
where it can be clearly seen that sleep restriction results in marked
wakefulness during this period compared to the “Pre” day. The
beginning of the sleep restriction period is also marked by the symbol
“▼” on the top x-axis. The symbol “Т” on the top and bottom x-axes
indicates when SRLT testing occurred each day, and the symbol “Δ” on
the top x-axis indicates when drugs were administered. The graphs on the
right are a zoomed view of the first 5 h of wakefulness following drug
administration. Asterisks refer to planned comparisons of drug treatment
groups against the respective Veh group for each study. *p<0.05;
**p<0.01; ***p<0.001
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significantly increased wakefulness for several hours follow-
ing dosing (Main Effects of Drug: modafinil F3,54=20.8,
p<0.0001; amphetamine F3,40=29.8, p<0.0001; caffeine F3,
35=11.3, p<0.0001; LSN2814617 F3,73=456.6, p<0.0001).
Increases in wakefulness caused by D-amphetamine, caf-
feine and LSN2814617 were dose dependent, although
only the highest dose (300 mg/kg) of modafinil induced
any significant effects. Wake-promoting effects of
modafinil, amphetamine and caffeine had effectively dis-
sipated by 3–5 h post-dose, while in contrast
LSN2814617 effects were larger in magnitude and more
persistent compared to the other compounds. The
highest dose of LSN2814617 tested (10 mg/kg) induced
a near 100% wakefulness throughout the subsequent
12 h dark phase.
SRLT functional effects The effects of sleep restriction and
drug administration on the simple response latency task are
depicted in Fig. 4. A qualitatively consistent effect of sleep
restriction was present across all four drug studies, whereby a
marked, significant decrease in completed trials (vehicle
group, planned comparisons of BPre^ day to BTest^ day per-
formance, modafinil p<0.0001; amphetamine p=0.013; caf-
feine p=0.002; LSN2814617 p<0.0001) and increase in
omissions (vehicle group, planned comparisons of BPre^ day
to BTest^ day performance, modafinil p<0.0001; amphet-
amine p=0.01; caffeine p=0.001; LSN2814617 p<0.0001)
was evident. Sleep restriction significantly decreased prema-
ture responding in three out of four studies (vehicle group,
planned comparisons of BPre^ day to BTest^ day, modafinil
p=0.001; amphetamine p=0.012; LSN2814617 p=0.001),
Fig. 4 Pro-vigilant drug effects on SRLT response parameters in 11-h
sleep-restricted rats. The four main SRLT response parameters are
depicted from top to bottom in the following order: number of trials
completed, number of premature responses, number of omissions and
response latencies. The doses of drugs depicted were 300 mg/kg
modafinil, 1 mg/kg amphetamine, 12 mg/kg caffeine and 3 mg/kg
LSN2814617. For individual graphs, the x-axis depicts the summary of
each measure for the “Pre”, “Test” and “Post” drug administration test
session. Asterisks refer to planned comparisons of Veh versus Drug
treatment within a test session for each study, where *p<0.05;
**p<0.01; ***p<0.001. Carets refer to planned comparisons for either
Veh (light grey) or Drug (black) treatments between test sessions, where
^p<0.05; ^^p<0.01; ^^^p<0.001, in comparison to the “Pre” session.
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while also showing a nominal decrease in the caffeine study.
Response latencies were significantly increased in the
modafinil and LSN2814617 studies by sleep restriction (vehi-
cle group, planned comparisons of BPre^ day to BTest^ day,
modafinil p=0.023; LSN2814617 p=0.012), but not in the
amphetamine and caffeine studies. With the exception of an
increase in omissions during the LSN2814617 study, no sig-
nificant carry-over effects of sleep restriction could be detect-
ed on any SRLT parameter during the BPost^ test session.
When drug doses were chosen for comparison on the basis
of pragmatically equivalent pro-vigilant effects on EEG pa-
rameters (300 mg/kg modafinil, 1 mg/kg amphetamine,
12 mg/kg caffeine, and 3 mg/kg LSN2814617), their effects
on sleep restriction-impaired task performance were markedly
different. Modafinil, caffeine and LSN2814617 all significant-
ly normalized sleep restriction-impaired performance with re-
gard to both trials completed (BTest^ day, planned compari-
sons of BVeh^ to BDrug^ group performance, modafinil p=
0.046; caffeine p=0.005; LSN2814617 p=0.014) and omis-
sions (BTest^ day, planned comparisons of BVeh^ to BDrug^
group performance, modafinil p=0.002; caffeine p=0.001;
LSN2814617 p=0.018) measures. Both caffeine and
modafinil significantly increased premature responding
(BTest^ day, planned comparisons of BVeh^ to BDrug^ group
performance, modafinil p=0.005; caffeine p=0.034) follow-
ing dosing after sleep restriction. The effect of modafinil was
particularly marked for this parameter, where premature re-
sponse rate more than doubled during the BTest^ session.
LSN2814617 did not significantly affect premature response
rates following administration. With regard to response laten-
cy, both caffeine and modafinil displayed a non-significant
trend towards decreasing this measure on test day (BTest^
day, planned comparisons of BVeh^ to BDrug^ group perfor-
mance, modafinil p=0.058; caffeine p=0.057), while
LSN2814617 was without effect. In dramatic comparison to
these three compounds, all of which showed some evidence of
functionally improving performance capacity following sleep
restriction, animals dosed with D-amphetamine could not com-
plete the SRLT task properly. On BTest^ day, D-amphetamine-
treated animals displayed a further marked and significant de-
crease in completed trials (BTest^ day, planned comparisons of
BVeh^ to BDrug^ group performance, amphetamine p=0.008),
increase in omissions (BTest^ day, planned comparisons of
BVeh^ to BDrug^ group performance, amphetamine p=0.008)
and a dramatic increase in response latencies (BTest^ day,
planned comparisons of BVeh^ to BDrug^ group performance,
amphetamine p=0.008). Finally, in terms of a BPost^ session
testing impairment, only modafinil displayed a small but signif-
icant decrease in trials completed (BTest^ day, planned compar-
isons of BVeh^ to BDrug^ group performance, modafinil
p=0.027) and increase in omissions (BTest^ day, planned com-
parisons of BVeh^ to BDrug^ group performance, modafinil
p=0.041) and response latency on the day following dosing.
Sleep parameters and compensatory sleep response
effects. By comparison to the same time period the day be-
fore, the biofeedback method of sleep restriction caused a loss
of approximately 6 h NREM sleep (Fig. 5). In the BDrug
Treatment^ period after sleep restriction, vehicle-treated ani-
mals recovered 90–120 min NREM sleep and 38–47 min
REM sleep. Both D-amphetamine and caffeine significantly
decreased the amount of NREM sleep recovered by animals
during this period (amphetamine F1,8=15.7, p=0.004; caf-
feine F1,7=36.4, p=0.001), while modafinil also showed a
non-significant trend towards the same effect (modafinil F1,
13=3.5, p=0.084). LSN2814617 had the most marked effect
of all of the drugs tested, where animals significantly incurred
further sleep debt, losing a further 2 h of NREM sleep during
this period relative to controls (LSN2814617 F1,16=397.9,
p<0.0001). All drug treatment groups showed some level of
NREM recovery during the subsequent day (Table 1). D-am-
phetamine- and caffeine-treated animals displayed a signifi-
cant increase in NREM sleep during the subsequent light
phase (amphetamine F1,8=14.4, p=0.005; caffeine F1,7=
11.2, p=0.012), while for modafinil-treated animals it was
delayed to the subsequent dark phase (modafinil F1,13=
15.5, p=0.002). LSN2814617-treated animals displayed
increases in NREM sleep during both subsequent light
and dark phases (BRebound Light^ F1,16=13.1, p=
0.002; BRebound Dark^ F1,16=23.6, p<0.0001).
Drug effects on REM sleep profile following sleep restriction
are shown in Fig. 6. All animals lost just over 40 min of REM
sleep time during the sleep restriction period, which in vehicle-
treated animals was almost completely recovered during the
BDrug Treatment^ period. All four compounds significantly de-
creased the amount of REM sleep recovered during this period
(modafinil F1,13=5.6, p=0.035; amphetamine F1,8=7.4, p=
0.026; caffeine F1,7=6.2, p=0.042; LSN2814617 F1,16=133.7,
p<0.0001), while for LSN2814617 animals significantly accu-
mulated a further 20 min of REM sleep debt. During the subse-
quent day, D-amphetamine and caffeine did not show significant
REM compensatory sleep effects, although there was a non-
significant trend for caffeine to increase REM sleep during the
subsequent light phase (caffeine F1,7=4.1, p=0.083). Modafinil
displayed amodest but significant increase in REM sleep during
the subsequent light period (modafinil F1,13=5.8, p=0.031).
LSN2814617 displayed the strongest REM compensatory ef-
fect, bymarkedly and significantly increasingREMsleep during
both the subsequent light and dark phase (BRebound Light^
F1,16=71.3, p<0.0001; BRebound Dark^ F1,16=6.1, p=0.025).
Discussion
By using an EEG biofeedback-induced sleep restriction meth-
odology, reliable and quantifiable levels of sleep restriction
were induced in rats that could be behaviourally indexed by a
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variant of the psychomotor vigilance test. The administration of
exemplar pro-vigilant compounds, at doses with broadly com-
parable effects on EEG sleep-wake parameters, demonstrated
that it was possible to determine differences in the capacity for
task engagement induced by different agents. mGlu5 PAMs
were identified as a novel pharmacological class of pro-
Fig. 5 The effect of pro-vigilant compounds on non-REM sleep
parameters in 11 h sleep-restricted rats. The graphs on the left depict a
72 h plot of time spent in non-REM sleep for modafinil (300 mg/kg), D-
amphetamine (1 mg/kg), caffeine (12 mg/kg) and LSN2814617
(3 mg/kg) studies, thereby including “Pre”, “Test” and “Post” drug
administration days. The x-axis depicts Circadian Time, where the solid
bars above the bottom x-axis between CT12-0 indicate when dark phases
occurred. Vertical dotted lines at CT0 and CT11 depict the beginning and
end of the sleep restriction period, where it can be clearly seen that sleep
restriction results in marked wakefulness during this period compared to
the “Pre” day. The beginning of the sleep restriction period is also marked
by the symbol “▼” on the top x-axis. The symbol “Т” on the top and
bottom x-axes indicates when SRLT testing occurred each day, and the
symbol “Δ” on the top x-axis indicates when drugs were administered.
The graphs on the right are summary measures of the differential amounts
of REM sleep achieved by rats between different circadian phases of the
study. The different measures were calculated as follows: Sleep
Dep=“Test” Light Phase–“Pre” Light Phase; Drug Treatment=“Test”
Dark Phase–“Pre” Dark Phase; “Recovery” Light=“Post” Light
Phase–“Pre” Light Phase; “Recovery” Dark=“Post” Dark Phase–
“Pre” Dark Phase. Asterisks refer to planned comparisons of drug
treatment groups against the respective Veh group for each study.
*p<0.05; **p<0.01; ***p<0.001
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vigilant drugs that induce a functionally distinct form of capac-
ity for task engagement compared to the existing standards
modafinil, amphetamine and caffeine.
The study of sleep restriction in rats has been fraught
with methodological issues, which can generate confounds
related to stress (Coenen and van Luijtelaar 1985;
Rechtschaffen et al. 2002; Wurts and Edgar 2000) or re-
quire additional groups to control for activity/fatigue (e.g.
Christie et al. 2008). In the present study, the EEG
biofeedback-induced cage rotation protocol employed the
minimum amount of movement necessary to wake the
animal via vestibular reflex upon detection of an epoch
of sleep, minimising both stress and movement confounds
as best as possible. This work also benefited from quan-
tification of EEG parameters throughout, allowing exact
definition of the sleep-wake state of animals during both
restriction and recovery periods. To date, very few behav-
ioural pharmacological studies in sleep restricted rats have
collected such information to guide interpretation.
When an 11 h sleep restriction was applied prior to the
performance of a SRLT, rats very consistently lost around
6 h of NREM sleep and 40min of REM sleep. This magnitude
of sleep loss was sufficient to cause behavioural impairment
on the SRLT task where the most marked effect was a large
increase in errors of omission, accompanied by a smaller de-
crease in premature response rate and lengthening of RT. In
humans, such effects on PVT performance can be observed
after experimental total sleep deprivation or chronic sleep
fragmentation (Van Dongen et al. 2003), but also as a conse-
quence of clinically presented EDS (Czeisler et al. 2005;
Dinges and Weaver 2003). A noticeable qualitative difference
was evident between rat SRLTand human PVTwith regard to
sleep restriction effects on the RT parameter itself. These are
very reliably detected in human studies, with performance
lapses (i.e. RTs>500 ms) being a defining hallmark of sleep
restriction (Lim and Dinges 2008). However, during rat SRLT
performance, the effects of sleep restriction on RTappeared to
be relatively smaller. Future work should determine whether
such discrepancies are related to motivational factors (i.e.
animals responding for food versus humans adhering to verbal
instruction), attentional load and/or arousal level differences.
Little preclinical work has actually studied the effect of sleep
restriction on attentional processes in rodents, but the present
results do display broad consistencies with the small, extant
literature. For instance, it has been shown in rats that 24 h sleep
deprivation (constant wheel turning method) followed by a
PVT-like task (Christie et al. 2008) and 10 h total sleep depri-
vation (gentle handling method) followed by 5-choice serial RT
testing (Cordova et al. 2006) impaired task performance. In
both cases, response latencies and omissions/lapses increased
significantly as a result of increased sleepiness, although the
number of premature responses did not change. The induction
of a change in premature response rate by sleep restriction may
therefore depend on subtleties of assay protocols employed.
The most important overall finding from the present study
was that different pro-vigilant pharmacologies had differential
effects on the ability to restore rat SRLT performance despite all
having significant effects on sleep/wake as assessed by EEG
parameters. Of the four compounds tested, amphetamine
(1 mg/kg) was the only drug to have marked negative effect
on performance capacity of sleep-restricted animals, such that
they completely disengaged from the task. Omissions increased
drastically, and when animals did complete trials they occurred
with very long response latencies. This profile is suggestive that
this dose of amphetamine, while wake-promoting in EEG mea-
sures, results in the expression of stimulant hyperactivity in
sleep-restricted rats that competes with task engagement. This
represents a potentially important disconnect to existing clinical
data, whereby most human studies report positive effects of
standard 10 or 20 mg amphetamine doses on attentional and
other cognitive tasks following sleep deprivation (see review
by Minzenberg and Carter 2008). By comparison, caffeine
(12 mg/kg), modafinil (300 mg/kg) and the mGlu5 PAM
LSN2814617 (3 mg/kg) all had beneficial effects on SRLT per-
formance in sleep-restricted rats. All three compounds signifi-
cantly decreased omissions and increased the number of trials
completed, allowing sleep-restricted animals to engage in the
task more effectively. Caffeine and modafinil also displayed a
Table 1 Summary of pro-
vigilant drug effects on sleep
recovery parameters in sleep-
restricted rats. Values presented
are means and standard errors of
the mean
Vigilance state Deficit (min) Recovery (min) Recovery (%)
Vehicle Non-REM 253±4 145±5 57
REM 47±2 39±3 82
D-Amphetamine (1 mg/kg) Non-REM 45±11 40±8 89
REM 21±8 11±4 53
Caffeine (12 mg/kg) Non-REM 83±14 49±15 59
REM 19±8 9±6 46
Modafinil (300 mg/kg) Non-REM 35±19 21±7 60
REM 15±6 12±5 84
LSN2814617 (3 mg/kg) Non-REM 239±12 54±6 23
REM 54±5 38±5 70
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trend-level tendency towards normalizing response latencies,
although both compounds also had concomitant negative effects
on premature response rates. Increases in premature responses
were especially dramatic following modafinil administration,
almost trebling in rate during the test session immediately fol-
lowing sleep restriction. Again, this finding is somewhat at odds
with clinical data, which describes modafinil to be well tolerated
with largely positive effects on human performance capacity and
Fig. 6 The effect of pro-vigilant compounds onREM sleep parameters in
11 h sleep-restricted rats. The graphs on the left depict a 72 h plot of time
spent in REM sleep for modafinil (300 mg/kg), D-amphetamine
(1 mg/kg), caffeine (12 mg/kg) and LSN2814617 (3 mg/kg) studies,
thereby including “Pre”, “Test” and “Post” drug administration days.
The x-axis depicts Circadian Time, where the solid bars above the
bottom x-axis between CT12-0 indicate when dark phases occurred.
Vertical dotted lines at CT0 and CT11 depict the beginning and end of
the sleep restriction period, where it can be clearly seen that sleep
restriction results in marked wakefulness during this period compared
to the “Pre” day. The beginning of the sleep restriction period is also
marked by the symbol “▼” on the top x-axis. The symbol “Т” on the
top and bottom x-axes indicates when SRLT testing occurred each day,
and the symbol “Δ” on the top x-axis indicates when drugs were
administered. The graphs on the right are summary measures of the
differential amounts of REM sleep achieved by rats between different
circadian phases of the study. The different measures were calculated as
follows: Sleep Dep=“Test” Light Phase–“Pre” Light Phase; Drug
Treatment=“Test” Dark Phase–“Pre” Dark Phase; “Recovery”
Light=“Post” Light Phase–“Pre” Light Phase; “Recovery”
Dark=“Post” Dark Phase–“Pre” Dark Phase. Asterisks refer to
planned comparisons of drug treatment groups against the respective
Veh group for each study. *p<0.05; **p<0.01; ***p<0.001
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response inhibition parameters (Minzenberg and Carter 2008).
Preclinical modafinil effects have been much more mixed, how-
ever, with reports of positive effects on stop signal (Eagle et al.
2007) and 5-choice serial RT (5CSRT) performance (Morgan
et al. 2007) in normal animals, but negative effects on accuracy
and impulse control in 5CSRT in normal (Waters et al. 2005)
and REM sleep deprived (disc over water method) animals (Liu
et al. 2011) in other studies. Several variables, including strain
and age of animals, dose of modafinil, assay designs and proto-
col variants, may need to be carefully considered here to under-
stand this mixture of effects.
ThemGlu5 PAMLSN2814617was found to have a remark-
ably powerful effect on EEG-defined wakefulness, consider-
ably larger and more enduring than the effects observed for
the other agents tested. Previous work onmGlu5 pharmacology
has suggested that potentiation at this receptor can promote
EEG-defined wakefulness in normal animals (Ahnaou et al.
2015; Gilmour et al. 2013; Gregory et al. 2013). Ahnaou and
colleagues found that a 3 mg/kg dose of LSN2814617 en-
hanced slow alpha band oscillatory activity (defined as 8–
11 Hz activity in their study) and reduced functional network
connectivity, which the authors suggested may have been in-
dicative of potential for impairment of cognition following dos-
ing. In the present study, a 3 mg/kg LSN2814617 dose also
increased power across an 8–11 Hz frequency band (data not
presented), but by extending assessment of LSN2814617 to the
measurement of functional capacity in a sleep-restricted state,
the question related to the potential for cognitive impairment
could also be addressed. LSN2814617 actually presented with
the ability to restore functional capacity in sleep-restricted rats,
displaying similar positive effects as modafinil and caffeine on
trials completed and omission measures, but lacking significant
effect on premature responding. Little is known at present as to
why this pharmacology has such a marked effect on vigilance,
although it may relate to the ability of mGlu5 receptor activa-
tion to directly and indirectly promote excitatory transmission
via the NMDA receptor (Bird and Lawrence 2009). In a
broader sense, the hypothesis that promotion of excitatory glu-
tamatergic neurotransmission could be a potential mechanism
of pro-vigilant effects is also substantiated by work on
AMPAkine pharmacology. In this regard, the AMPA receptor
PAM CX717 can restore performance of a delayed match-to-
sample task in sleep deprived (gentle handling) nonhuman pri-
mates (Porrino et al. 2005), whilst also normalizing sleep
deprivation-induced decreases in NMDA-mediated intracellu-
lar calcium release in the hippocampus (Hampson et al. 2009).
Unfortunately, these effects have not yet translated into robust
responses in clinical trials (Boyle et al. 2012; Wesensten et al.
2007), possibly due to lack of a direct measure of target en-
gagement to inform human dosing regimens. Beyond gluta-
mate, interactions of the mGlu5 receptor with other mecha-
nisms postulated to play a role in sleep-wake regulation may
also be important, for example Homer 1a (Ango et al. 2001;
Ango et al. 2002; Maret et al. 2007) or adenosinergic transmis-
sion (Bachmann et al. 2012; Bodenmann et al. 2012; Gallopin
et al. 2005; Okada et al. 2003). Finally, a recent PET imaging
study in humans using the selective radioligand 11C-ABP688
has demonstrated that mGlu5 receptor availability is increased
in several brain regions after one night of sleep deprivation
(Hefti et al. 2013), which suggests that dynamic changes in
mGlu5 receptor expression may play a fundamental role in
sleep/wake homeostasis.
It is clear that a homeostatic process tracks the loss of sleep
as a Bsleep pressure^ that will result in a dose-dependent com-
pensation proportional to the debt accrued (Daan et al. 1984;
Dijk et al. 1990). All treatments compared in the present study
resulted in immediate attenuation of the compensatory sleep
response elicited by 11 h of sleep restriction. However, the
proportion of sleep pressure immediately relieved following
pro-vigilant treatment was later recovered to a degree during
the subsequent recording period, suggesting that requirement
for homeostatic sleep was not completely alleviated by any
compound. The most rapid and complete compensatory sleep
response was observed for D-amphetamine, whilst both caf-
feine and modafinil produced equivalent proportions of
NREM sleep recovery relative to the additional wakefulness
gained. The greatest differential effect was observed for
LSN2814617, where animals appeared to only recover 22%
of lost NREM sleep versus 70% of REM sleep. This finding is
interesting, as it is more typical for NREM sleep recovery to
precede or at least occur concomitantly with REM sleep re-
covery (Berger and Oswald 1962; Borbely and Neuhaus
1979). Future work should consider how the relatively distinct
effects of LSN2814617 onNREM versus REM compensatory
sleep responses and performance capacity may be related.
In conclusion, the present study demonstrated that a PVT-
like SRLT can be used in rats to detect behavioural impair-
ments caused by a quantified loss of sleep. An mGlu5 PAM
molecule was shown to produce marked wakefulness and an
improvement in functional capacity of sleep-restricted ani-
mals, qualitatively distinct from that of amphetamine, caffeine
and modafinil. The methodology and novel pharmacological
effects described may offer utility for future work directed at
understanding the translational correspondence of pro-vigilant
drug effects between species.
Funding and disclosure At the time of completion of these studies, all
authors were employees of Eli Lilly & Co. Ltd.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
Psychopharmacology (2015) 232:3977–3989 3987
References
Ahnaou A, Langlois X, Steckler T, Bartolome-Nebreda JM, Drinkenburg
WHIM (2015) Negative versus positive allosteric modulation of me-
tabotropic glutamate receptors (mGluR5): Indices for potential pro-
cognitive drug properties based on EEG network oscillations and
sleep-wake organization in rats. Psychopharmacology 232:1107–1122
Akerstedt T, Philip P, Capelli A, Kecklund G (2011) Sleep loss and
accidents—Work hours, life style, and sleep pathology. Prog Brain
Res 190:169–188
Anderson C,Wales AW, Horne JA (2010) PVT lapses differ according to
eyes open, closed, or looking away. Sleep 33:197–204
Ango F, Prezeau L, Muller T, Tu JC, Xiao B,Worley PF, Pin JP, Bockaert
J, Fagni L (2001) Agonist-independent activation of metabotropic
glutamate receptors by the intracellular protein Homer. Nature 411:
962–965
Ango F, Robbe D, Tu JC, Xiao B, Worley PF, Pin JP, Bockaert J, Fagni L
(2002) Homer-dependent cell surface expression of metabotropic
glutamate receptor type 5 in neurons. Mol Cell Neurosci 20:323–
329
Bachmann V, Klaus F, Bodenmann S, Schafer N, Brugger P, Huber S,
Berger W, Landolt HP (2012) Functional ADA polymorphism in-
creases sleep depth and reduces vigilant attention in humans. Cereb
Cortex 22:962–970
Balkin TJ, Bliese PD, Belenky G, Sing H, Thorne DR, Thomas M,
Redmond DP, Russo M, Wesensten NJ (2004) Comparative utility
of instruments for monitoring sleepiness-related performance decre-
ments in the operational environment. J Sleep Res 13:219–227
Basner M, Dinges DF (2011) Maximizing sensitivity of the psychomotor
vigilance test (PVT) to sleep loss. Sleep 34:581–591
BERGER RJ, OSWALD I (1962) Effects of sleep deprivation on behav-
iour, subsequent sleep, and dreaming. J Ment Sci 108:457–465
Bird MK, Lawrence AJ (2009) The promiscuous mGlu5 receptor—a
range of partners for therapeutic possibilities? Trends Pharmacol
Sci 30:617–623
Bodenmann S, Hohoff C, Freitag C, Deckert J, Retey JV, Bachmann V,
Landolt HP (2012) Polymorphisms of ADORA2A modulate psy-
chomotor vigilance and the effects of caffeine on neurobehavioural
performance and sleep EEG after sleep deprivation. Br J Pharmacol
165:1904–1913
Borbely AA, Neuhaus HU (1979) Sleep-deprivation: Effects on sleep and
EEG in the rat. J Comp Physiol 133:71–87
Boulos MI, Murray BJ (2010) Current evaluation and management of
excessive daytime sleepiness. Can J Neurol Sci 37:167–176
Boyle J, Stanley N, James LM, Wright N, Johnsen S, Arbon EL, Dijk DJ
(2012) Acute sleep deprivation: the effects of the AMPAKINE com-
pound CX717 on human cognitive performance, alertness and re-
covery sleep. J Psychopharmacol 26:1047–1057
Chellappa SL, Schroder C, Cajochen C (2009) Chronobiology, excessive
daytime sleepiness and depression: is there a link? Sleep Med 10:
505–514
Christie MA, McKenna JT, Connolly NP, McCarley RW, Strecker RE
(2008) 24 hours of sleep deprivation in the rat increases sleepiness
and decreases vigilance: Introduction of the rat-psychomotor vigi-
lance task. J Sleep Res 17:376–384
Coenen AM, van Luijtelaar EL (1985) Stress induced by three procedures
of deprivation of paradoxical sleep. Physiol Behav 35:501–504
Cordova CA, Said BO, McCarley RW, Baxter MG, Chiba AA, Strecker
RE (2006) Sleep deprivation in rats produces attentional impair-
ments on a 5-choice serial reaction time task. Sleep 29:69–76
Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, Kingsbury L,
Arora S, Schwartz JR, Niebler GE, Dinges DF, U.S. Modafinil in
Shift Work Sleep Disorder Study Group (2005) Modafinil for ex-
cessive sleepiness associated with shift-work sleep disorder. N Engl
J Med 353:476–486
Daan S, Beersma DG, Borbely AA (1984) Timing of human sleep:
Recovery process gated by a circadian pacemaker. Am J Physiol
246:R161–83
Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007) Systemic and
nasal delivery of orexin-A (Hypocretin-1) reduces the effects of
sleep deprivation on cognitive performance in nonhuman primates.
J Neurosci 27:14239–14247
Dijk DJ, Brunner DP, Beersma DG, Borbely AA (1990)
Electroencephalogram power density and slowwave sleep as a func-
tion of prior waking and circadian phase. Sleep 13:430–440
Dinges DF, Powell JW (1985) Microcomputer analyses of performance
on a portable, simple visual RT task during sustained operations.
Behav Res Methods Instrum Comput 17:652–655
Dinges DF,Weaver TE (2003) Effects of modafinil on sustained attention
performance and quality of life in OSA patients with residual sleep-
iness while being treated with nCPAP. Sleep Med 4:393–402
Eagle DM, Tufft MR, Goodchild HL, Robbins TW (2007) Differential
effects of modafinil and methylphenidate on stop-signal reaction
time task performance in the rat, and interactions with the dopamine
receptor antagonist cis-flupenthixol. Psychopharmacology (Berl)
192:193–206
Gallopin T, Luppi PH, Cauli B, Urade Y, Rossier J, Hayaishi O,
Lambolez B, Fort P (2005) The endogenous somnogen adenosine
excites a subset of sleep-promoting neurons via A2A receptors in the
ventrolateral preoptic nucleus. Neuroscience 134:1377–1390
Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM, Fivush A,
Gastambide F, Getman B, Heinz BA, McCarthy AP, Prieto L,
Shanks E, Smith JW, Taboada L, Edgar DM, Tricklebank MD
(2013) In vitro characterisation of the novel positive allosteric mod-
ulators of the mGlu(5) receptor, LSN2463359 and LSN2814617,
and their effects on sleep architecture and operant responding in
the rat. Neuropharmacology 64:224–239
Gregory KJ, Herman EJ, Ramsey AJ, Hammond AS, Byun NE, Stauffer
SR, Manka JT, Jadhav S, Bridges TM, Weaver CD, Niswender CM,
Steckler T, Drinkenburg WH, Ahnaou A, Lavreysen H, Macdonald
GJ, Bartolome JM, Mackie C, Hrupka BJ, Caron MG, Daigle TL,
Lindsley CW, Conn PJ, Jones CK (2013) N-aryl piperazine metab-
otropic glutamate receptor 5 positive allosteric modulators possess
efficacy in preclinical models of NMDAhypofunction and cognitive
enhancement. J Pharmacol Exp Ther 347:438–457
HampsonRE, Espana RA, Rogers GA, Porrino LJ, Deadwyler SA (2009)
Mechanisms underlying cognitive enhancement and reversal of cog-
nitive deficits in nonhuman primates by the ampakine CX717.
Psychopharmacology (Berl) 202:355–369
Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM,
Scheidegger M, Berthold T, Gomez-Mancilla B, Seifritz E,
Landolt HP (2013) Increased metabotropic glutamate receptor sub-
type 5 availability in human brain after one night without sleep. Biol
Psychiatry 73:161–168
Knie B, Mitra MT, Logishetty K, Chaudhuri KR (2011) Excessive day-
time sleepiness in patients with Parkinson’s disease. CNS Drugs 25:
203–212
Lim J, Dinges DF (2008) Sleep deprivation and vigilant attention. Ann N
YAcad Sci 1129:305–322
Liu YP, Tung CS, Lin YL, Chuang CH (2011) Wake-promoting agent
modafinil worsened attentional performance following REM sleep
deprivation in a young-adult rat model of 5-choice serial reaction
time task. Psychopharmacology (Berl) 213:155–166
Ly S, Pishdari B, Lok LL, HajosM, Kocsis B (2013) Activation of 5-HT6
receptors modulates sleep-wake activity and hippocampal theta os-
cillation. ACS Chem Neurosci 4:191–199
Maret S, Dorsaz S, Gurcel L, Pradervand S, Petit B, Pfister C,
Hagenbuchle O, O’Hara BF, Franken P, Tafti M (2007) Homer1a
is a core brain molecular correlate of sleep loss. Proc Natl Acad Sci
U S A 104:20090–20095
3988 Psychopharmacology (2015) 232:3977–3989
Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical
actions and effects on cognition. Neuropsychopharmacology 33:
1477–1502
Morgan RE, Crowley JM, Smith RH, LaRoche RB, Dopheide MM
(2007) Modafinil improves attention, inhibitory control, and reac-
tion time in healthy, middle-aged rats. Pharmacol Biochem Behav
86:531–541
Okada T, Mochizuki T, Huang ZL, Eguchi N, Sugita Y, Urade Y,
Hayaishi O (2003) Dominant localization of adenosine deaminase
in leptomeninges and involvement of the enzyme in sleep. Biochem
Biophys Res Commun 312:29–34
Porrino LJ, Daunais JB, Rogers GA,HampsonRE, Deadwyler SA (2005)
Facilitation of task performance and removal of the effects of sleep
deprivation by an ampakine (CX717) in nonhuman primates. PLoS
Biol 3:e299
Rechtschaffen A, Bergmann BM, Everson CA, Kushida CA, Gilliland
MA (2002) Sleep deprivation in the rat: X. Integration and discus-
sion of the findings. 1989. Sleep 25:68–87
Roth T, Roehrs TA (1996) Etiologies and sequelae of excessive daytime
sleepiness. Clin Ther 18:562–76, discussion 561
Stocking EM, Letavic MA (2008) Histamine H3 antagonists as wake-
promoting and pro-cognitive agents. Curr Top Med Chem 8:988–
1002
Van Dongen HP, Dinges DF (2000) Circadian rhythmin sleepiness, alert-
ness and performance. In: Kryger MH, Roth T, Dement WC (eds)
Principles and practice of sleep medicine. W.B. Saunders,
Philadelphia, pp 435–443
Van Dongen HP, Maislin G, Mullington JM, Dinges DF (2003) The
cumulative cost of additional wakefulness: Dose–response effects
on neurobehavioral functions and sleep physiology from chronic
sleep restriction and total sleep deprivation. Sleep 26:117–126
Waters KA, Burnham KE, O’connor D, Dawson GR, Dias R (2005)
Assessment of modafinil on attentional processes in a five-choice
serial reaction time test in the rat. J Psychopharmacol 19:149–158
Wesensten NJ, Reichardt RM, Balkin TJ (2007) Ampakine (CX717)
effects on performance and alertness during simulated night shift
work. Aviat Space Environ Med 78:937–943
Wurts SW, Edgar DM (2000) Circadian and homeostatic control of rapid
eye movement (REM) sleep: Promotion of REM tendency by the
suprachiasmatic nucleus. J Neurosci 20:4300–4310
Psychopharmacology (2015) 232:3977–3989 3989
